MacroGenics to Present at H.C. Wainwright 27th Annual Global Investment Conference

Core Viewpoint - MacroGenics, Inc. is set to present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, highlighting its focus on innovative antibody-based therapeutics for cancer treatment [1]. Company Overview - MacroGenics is a biopharmaceutical company dedicated to developing monoclonal antibody-based therapeutics specifically for cancer treatment [3]. - The company utilizes proprietary next-generation antibody-based technology platforms to generate its pipeline of product candidates, which have broad therapeutic applications [3]. - MacroGenics combines its technology platforms with protein engineering expertise to create promising product candidates and has established several strategic collaborations with global pharmaceutical and biotechnology companies [3].